Buzz. SGCP on the rise

Sierra Gold Corp (SGCP)

$ 0.0023 ▲0.0002 (9.52%)

Volume: 20,854,169

Up nearly 40% since Monday.

Not a bad week so far for SGCP share holders. With the entirety of today’s 9.52% increase being in the last two hours I’d say the run will continue through Friday.

As I’ve mentioned in my previous posts the penny’s are all about hype. Today SGCP appeared on the Most Active Forums at Investorshub.com, thehotpennystocks.com, and  ddmachine.com. The volume increased as did the share price. So whats all the hype about?

Production numbers.  With a fleet of dredges finally in the water, the amount of gold SGCP can pull from the river beds should be significantly higher. The big release is approaching and I predict SGCP goes up as people jump in, not wanting to miss the boat.  If the numbers are better than expected the stock could possibly find its price in the penny’s. But there is always a chance the numbers will not impress and the price will fall back down. Penny stocks are always a risk, and I will reiterate the importance of selling in increments  as the price rises during these hype build ups so that you don’t lose out completely in the worst case scenario.

As for tomorrow I expect the stock to keep rising simply because people will be buying in before the weekend.

As always this post is entirely my opinion only, always do your own DD, and have a great afternoon!

-TG

Anticipating SGCP

Sierra Gold Corp. – SGCP

$ 0.002 ▲0.0003 (17.65%)

Volume: 20,774,700

–As the worlds economies continue to suffer we are seeing a gold rush. The precious metal is more secure than paper currency. As the price of gold continues to rise it makes sense to put some of your money in the companies that will be benefitting from the up trend, especially the companies that are producing it. –

There hasn’t been so much action for investors with SGCP this year. A few opportunities to flip a little but quiet for the most part. Though that doesn’t necessarily mean nothing’s been happening in Sierra Leone.

The company has been preparing for what looks to be the most profitable mining season they’ve had yet. With 5 dredges already in the water and plans for adding more in the near future, investors await their first taste  of production numbers and earnings as a profitable mining company. This is going to be a massive change in terms of production, considering they are just now standing on two feet as a “producing” mining company..

No matter what the numbers are it will be an improvement but if the numbers are good we are possibly looking at a sub-penny stock moving to pennies in one day. This is the kind  action that makes me love trading. That intense time shortly before the big event. This, in my experience, is the wave beginning to form. This is the time I would choose to get in because the price will rise with anticipation of the news. While the stocks rising a smart strategy might be to sell a fraction of your shares just before the PR is posted that way if the results are not as positive as was expected you won’t have lost out completely, and might even have some cash to purchase shares at a lower price for the next one.  As the results should only grow from here on out and the PR after this will likely bring the same kind of attention and anticipation.

I will be updating more in this time as the numbers get closer.

Until then  good luck out there and remember, this is entirely my opinion only. I HIGHLY suggest doing your own DD before purchasing any stock. Happy trading!

_TG

SGCP, XMDC, and CLWR Updated

It has been too long since I’ve posted and already it feels good to be back. My last post contained three picks of mine SGCP, XMDC, and CLWR. Here is my update.

• Sierra Gold Corp, SGCP has just released their first PR in months:

March 18, 2010 11:47 AM ET

---

Related Quotes
Sym.		Price	Chg.
SGCP	Trade News	0.0018	0.0001

Sierra Gold Announces Kiri Tree Purchase for Carbon Credit Program and Shipment of Mining Dredges to Sierra Leone

Mar 18, 2010 11:01:10 (ET)

TORONTO, Canada, Mar 18, 2010 (GlobeNewswire via COMTEX) — Sierra Gold Corporation (Pink Sheets:SGCP) announced today that it has made its first purchase of 1000 kiri trees for its carbon credit program. These fast growing trees are due to be shipped later this month and preparations are complete for their immediate planting upon arrival at their designated destinations within Sierra Leone.

Carbon Credits are allotted to companies that support the environment in such ways as committing designated forest land to non-logging operations; re-foresting previously logged or mined lands, and growing alternative bio-fuel crops. The funds received from the Carbon Credit programs will be utilized by the company to fund further development of its mining and agricultural operations in Sierra Leone. A number of world organizations have established these programs to enable companies to accumulate carbon credits that can be exchanged for money.

In addition, two “8″ dredges purchased last month have been completely refurbished and shipped this week to Sierra Leone. Experienced US dredge operators will travel to Sierra Leone at the end of March to prepare for the arrival of the equipment. The company will then commence operations and begin gold production.

Doug Evans, CEO of Sierra Gold, commented: “We are pleased to be able to move forward with both our carbon credit and mining projects. The trees and equipment provide our company a two pronged approach to create successful future and add to shareholder value.”

Sierra Gold is engaged in the exploration and development of gold and diamond properties in West Africa. The Birimian greenstone belt of West Africa has had a long history of gold mining and prospecting. The region has been one of the fastest gold producing areas worldwide.

Safe Harbor: No assurance can be given that past or similar results of precious metal mining will be indicative of future results. This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when used in the preceding of discussion, the words “pleased,” “plan,” “confident that,” “believe,” “expect,” or “intent to” and similar conditional expressions are intended to identity forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional financings and other risks in the company’s SEC reports and filings.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Sierra Gold Corporation

CONTACT: Sierra Gold Corporation

John Semacho Jr.
330-273-6183

This is good news but has had little effect (so far) on the fallen PPS. Most likely because many people don’t understand the carbon market and that this PR implies that gold production hasn’t even began. These dredges will get there just before the next rainy season so that won’t be good for production either, this is most likely why the PPS has not jumpled. In my humble opinion I would have thought after 6 months of nothing… not even crickets chirping… a PR of ANY kind would raise the PPS. I guess now it’s wait and see. Seems like next season will be a strong one and this is a good low point to jump in.

XMDC, Xtend Medical

The brilliant machines XMDC purchaced the rights to might still be a long time coming. It seems the owner of BIOHARP deciding to not want to follow through on his side of the deal. This is very bad news for XMDC as now they are trying to force him by law to follow through which means COSTS COSTS COSTS mostly at the shareholders expense. If they can get BIOHARP to comply than this thing will likely move up quick, but until then the PPS seems destined to fall like chubby rain. Since my last post it has fallen from .06 to .0070. If not already invested this could be a great entry point but I’d wait a little longer until theres word on Mr. Lee and Bioharp coming through for Xtend. If the deal goes MORE sour this things heading for tripple zeros.

CLWR, Clearwire

This company is poised to be huge. I don’t see it slowing down anytime soon. This is one of those I wish I’d invested in when I first heard about it. It’s the only one of my three to follow that has consistently been green. This will be at $10 soon without a doubt. Congrats to those who got in $3 ago!

Short but sweet update here folks. I’ll return with something more interesting soon. Until then  good luck out there and remember, this is all my opinion only. I HIGHLY suggest doing your own DD before purchasing any stock. Happy trading!

_TG

Three Stocks to Look Into

Here are three undervalued stocks to consider looking into.

SGCP – Sierra Gold Corp.

Current PPS:  0.0062

This little gold mine is actually not little at all. Not only do they mine for gold and other precious gems, but they also have been dedicated to being green. During the rainy seasons they have been farming to feed their employees and help with their local community. They have been approved to receive a *Carbon Credit, which means a rush of capital and productivity in the near future.

*A number of world organizations have established programs to enable companies to accumulate carbon credits that can be exchanged for money. Carbon Credits are allotted to companies that support the environment in such ways as committing designated forest land to non-logging operations; re-foresting previously logged or mined lands, and growing alternative bio-fuel crops. The funds received from the Carbon Credit programs will be utilized by the company to fund further development of its mining and agricultural operations in Sierra Leone. 

XMDC – XTend Medical Corp.

Current PPS: 0.04

I like XTend Medical because they are cheap… for now.

Sometime in the near future (1-6 months) XTend Medical will be merging with BioHarp, and will own the right to The BioHarp.

BioHarp is a cutting-edge medical imaging device that utilizes a non-invasive approach to detect inflammation in the human body on a cellular level. The device uses a complex scanning program that deciphers inflammation in the body’s organs through a bio-sensory system and allows early detection and diagnosis of potentially life threatening diseases. This hand-held diagnostic device is the first of its kind that can effectively scan the body and deliver a comprehensive report that can assist any physician in determining the proper course of treatment for patients in the EARLY STAGES of potentially life threatening diseases.

Each BioHarp will cost roughly around $30, 000 and will be sold to medical facilities internationally. 

CLWR – Clearwire

Current PPS: 5.85

CLEAR 4G WiMAX is next generation mobile internet from Clearwire that works as fast around town as it does at home. Because CLEAR covers a wide area you don’t have to find a hotspot—the hotspot goes with you, anywhere CLEAR has coverage.

This company looks poised for success as Sprint owns a majority and Time Warner purchased a huge number of shares. This is the next big thing in connecting to the internet and the internet is the future. The stock is low for such technology but that means it might be time to get in. Once this really catches the PPS will explode.

As always this is all my opinion only. Please make sure to do your own DD before investing in the stock market. 

~Trading Grasshopper

Genta, Come to Slaughter Follow Up

Today was rough for Genta but the PPS never fell under a penny. It did drop 70% but it held strong at a new (low) resistance level.  There were a lot of new buyers at this level and it seems the true measure of this stocks value will be known in the near future. With a strong pipeline still in place there is a chance of recovery.

AGENDA was not based solely around melanoma. Today seemed to be a huge over reaction to some bad news and I think that GETA will be gapping up in the morning.

There will be another conference call next Thursday. Until then I can’t give much more solid information.

 

This is in my opinion only, I strongly advise to do your own DD, and have a good evening.

 

-Trading Grasshopper

 

Genta, Come to Slaughter

The conference call this morning brought news that the drug had little significant effect on the survival rate of patients in it’s AGENDA trial. This is extremely disappointing news for most and it has started a pre-market panic sell. The price went from .65 to .14 before the market opened.

Though things seem rough I assume there will be a bounce and those who weren’t in before will buy in at these new low prices. I don’t see the bounce hitting anywhere near the heights this stock has seen, but in the stock market none is lost until you sell.

The outcome unknown but not likely pretty. The battle for Gentas PPS will be a bloody one.

Good  luck to all who have been passionately following this.

This is my opinion only, always do your own DD, and have a great day.

-Trading Grasshopper

Genta Conference Call in Less than 8 Hours!

After a stinker of a day news comes out for Genta!

Genta Incorporated Announces Conference Call to Review Top-Line Results of AGENDA Phase 3 Trial of Genasense® in Patients with Advanced Melanoma

 

• • BERKELEY HEIGHTS, N.J.–(BUSINESS WIRE)–Genta Incorporated (OTCBB: GETA – News) announced that the Company will host a conference call and live audio webcast to review top-line results of its Phase 3 trial of Genasense^® in patients with advanced melanoma. The call will take place on Thursday October 29, 2009 at 8:00 AM ET.

Related Quotes

Symbol	Price	Change
GETA.OB	0.65	-0.08

{“s” : “geta.ob”,”k” : “c10,l10,p20,t10″,”o” : “”,”j” : “”}

Participants can access the live call by dialing (877) 634-8606 (U.S. and Canada) or (973) 200-3973 (International). The access code for the live call is Genta Incorporated. The call will also be webcast live at http://www.genta.com/investorrelation/events.html.

For investors unable to participate in the live call, a replay will be available approximately two hours after the completion of the call, and will be archived for 30 days. Access numbers for this replay are: (800) 642-1687 (U.S. and Canada) and (706) 645-9291 (International); conference ID number is: 38149996.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company’s research platform: DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company’s lead compound from its DNA/RNA Medicines program. Genasense is being developed as an agent that may enhance the effectiveness of current anticancer therapy. The leading drug in Genta’s Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, which has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a “named-patient” basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact. The words “potentially”, “anticipate”, “could”, “calls for”, and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements. Factors that could affect actual results include, without limitation, risks associated with:

• the Company’s ability to obtain necessary regulatory approval for Genasense^® from the U.S. Food and Drug Administration (“FDA”);
• the safety and efficacy of the Company’s products or product candidates;
• the commencement and completion of clinical trials;
• the Company’s assessment of its clinical trials;
• the Company’s ability to develop, manufacture, license and sell its products or product candidates;
• the Company’s ability to enter into and successfully execute license and collaborative agreements, if any;
• the adequacy of the Company’s capital resources and cash flow projections, the Company’s ability to obtain sufficient financing to maintain the Company’s planned operations, or the Company’s risk of bankruptcy;
• the adequacy of the Company’s patents and proprietary rights;
• the impact of litigation that has been brought against the Company; and
• the other risks described under Certain Risks and Uncertainties Related to the Company’s Business, as contained in the Company’s Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company’s Annual Report on Form 10-K for 2008 and its most recent quarterly report on Form 10-Q.

 

I will post details about the conference call tomorrow.  I am not expecting this to be the BIG announcement but it should give the PPS a boost. Also tomorrow I am going to start researching different stocks as I am starting to feel like a one trick pony with Genta. Expect a diverse group very soon. Also I will be moving to my own site as soon as it’s completed, for now enjoy the wordpressing!

 

-Trading Grasshopper

New to Stock Trading?

Here is a nice little bit of info for those who are just starting out, posted by an admin on thepennyplay.com:

“Technology has widened the scope for tremendous growth in the stock market. Stock dealing on the Internet involves only execution of the orders. You can buy or sell your stocks from more than 100 online brokers instantly. Online trading is the quickest and the most convenient way of dealing in stocks.

Steps to trade stocks online:

The first step involves identifying a good online broker, to avail of inexpensive services and good (not to mention easy to use) tools.

Make sure that the online broker has an easy to navigate website. The web pages must load quickly, since you may have to look at more than one chart while you wait for the right price to buy or sell the stocks.

The trading screen should be well organized for you to double-check all the information before trading.

Do not opt for delayed quotes. A delay of 15-20 minutes can affect your chances of profit. Ensure that you avail of real time quotes. A good online broker will execute your interests as quickly as the stock moves a point. If there is an unnecessary delay in filling in the order, you could stand to lose.

 

Take time to choose the best online broker because the wrong choice can turn online trading into a nightmare. It pays to access the stock trading forums and conduct thorough research.

Reputed online brokers are equipped to provide quick confirmations on orders and offer account balance information and current portfolio updates.

Look for an undervalued company. Do not just buy the first over publicized share you come across in the headlines of the local business newspaper. Because publicity may increase the price and the market capital of a stock but it may not be beneficial for you as a buyer.

When the stock market drives down the price of a stock, you can make big money on the investment made after identifying that stock. This is due to the fact that stocks that fall hard are observed to bounce back and show good quarters for investors.

Your losses can be limited in the fast moving stock market, if you gather sufficient information on the stocks you intend to buy and the investment risk attached. Consider the long-term growth opportunities of a particular company before buying stocks online.

According to the wall street journal, if you have your stocks in a great company then the best time to sell your stocks is ‘never’. If you cancel the online trade, immediately contact your firm to ensure that the original transaction was not executed.

Always remember that trading of stocks online is not an instantaneous process. Technological ‘choke points’ (like a slow or faulty Internet Service Provider or computer) can slow down the process of your orders reaching the firm. You can also avail of telephone trade or faxing your order. However, these alternatives also come with similar delays.

When a number of investors trade at the same time, prices change and delays become unavoidable. As an investor, you could suffer unexpected loss. You should make sure that you understand all the nuances of buying and selling stocks online, before you make any moves.”

 

I will be posting much more in the near future. I would really like people to post more comments, ask more questions, give their take on things, and share advise with me as well as my readers. I wish everyone a great afternoon!

 

-Trading Grasshopper

Genta Website

Genta

www.genta.com

GETA

For a short time this morning Genta had a new website (leaked?), but it was removed quickly (after a surge of hits maybe?). Here is a screen grab.

And here is one of the pipeline:

This was posted by Ihubber "Smitter"

The new site looks much nicer than the current one and has some very interesting content including:

• An “updated” pipeline that had said that Tesetaxel had completed phase II for breast and gastric cancer.

• A new physical address.

• New job openings.

• Investor Relations page.

• A long list of events Genta plans to attend:

Society for Melanoma Research – International Congress
Sunday, November 01, 2009
To Wednesday, November 04, 2009Boston, MA

AACR-NCI-EORTC Molecular Targets And Cancer Therapeutic Conference
Sunday, November 15, 2009
To Thursday, November 19, 2009Boston, MA

Lazard Capital Markets
6th Annual Healthcare Conference
Tuesday, November 17, 2009
To Wednesday, November 18, 2009New York, NY

3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers
Thursday, November 19, 2009
To Saturday, November 21, 2009Berlin, Germany

American Society of Hematology
Saturday, December 05, 2009
To Tuesday, December 08, 2009New Orleans, LA

JP Morgan 28th Annual Healthcare Conference
Monday, January 11, 2010
To Thursday, January 14, 2010San Francisco, CA

American Society of Clinical Oncology (ASCO)
Friday, June 04, 2010
To Tuesday, June 08, 2010Chicago, IL

20th German Skin Cancer Conference
Thursday, September 23, 2010
To Saturday, September 25, 2010 Kiel, Germany

• Last but not least, a new corporate fact sheet

This is very encouraging as the first event on the list is just around the corner on Nov. 1st.  Could Genta finally be announcing results?  It seems to be a  possibility. Could the results be good? Based on all the new info (job openings, new physical address, new PIPELINE, long list of events) I’d say they very well could be.

What an exciting leak,  hopefully a window with a view of good things to come.

This is my opinion only, always do your own DD, and have a great afternoon!

-The Trading Grasshopper

EPIX up for Auction?

EPIX Pharmaceuticals

PRX-03140

EPIX-

There was lot’s of buzz this weekend about EPIX having an “FDA approved” drug auction on Wednesday. The buzz sent the stock up 1000% on Friday and investors seemed eager to jump in this morning. But the funny thing about hype is that it can be deceiving…

If you read the PR closely you will see it says that the FDA approved a “IND” which is an extension of a test.

So the drug didn’t get approved, a continued study of it did. Which means only the patients who participated in phase II will get to continue using it. The phase II trial only had one test subject, which is strange.

I’m sure it was picked for the auction because it is EPIX’s greatest asset. It will likely bring them the most money. However, how much money?

What is for sale here is the opportunity for a larger company to purchase a drug (PRX-03140) for a large market (Alzheimer’s) at a late stage of development. The cost of two trials is behind them, and there is a possibility they
could meet with the FDA and get a Phase III trial approved (which is
the last phase before big time approval), which is good but it would no longer be involved with THIS company
after the auction. Also there are some reasonable claims against the company, somewhere around
$5 million. So if the auction on Wednesday were to yield a far greater amount, say $30m, $25m would be left over for the benefit of the company and its shareholders.

This morning I predicted a price drop because people would realize the drug was not “FDA approved” but merely acquired permission to continue a study. Unfortunately the company is low on funds and is liquidizing their assets to get out with what ever profit they can, and PRX-03140 is their greatest asset. Hopefully it will get some high bids.

Because of the auction on Wednesday, tomorrow after noon might see a light run. But another 1000% doesn’t seem likely. The time to get in would have probably been last Thursday. For those who bought in today I hope I’m wrong.

This is my opinion only, always do your own DD, and have a great afternoon!

-The Trading Grasshopper